Перейти
на сайт журнала "Врач" |
Перейти на сайт журнала "Медицинская сестра"
|
Перейти на сайт журнала "Фармация"
|
Перейти на сайт журнала "Молекулярная медицина"
|
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
|
Журнал включен в российские и международные библиотечные и реферативные базы данных
ВАК (Россия)
|
РИНЦ (Россия)
|
Эко-Вектор (Россия)
|
ASSESSMENT OF THE HEPATOTOXIC POTENTIAL OF ORGANOTIN COMPOUNDS CONTAINING 2,6-DI-TERT-BUTYLPHENOL FRAGMENT
DOI: https://doi.org/10.29296/25877313-2021-08-03
Issue:
8
Year:
2021
The article is devoted to the in vivo study of the effect of organotin compounds containing 2,6-di-tert-butylphenol fragment on liver morpho-functional state. The aim of this study was to evaluate the biochemical and histological changes in the liver with a single intragastric administration of bis (3,5-di-tert-butyl-4-hydroxyphenylthiolate) dimethyltin (Me3) and (3,5-di-tert-butyl-4-hydroxyphenylthiolate) triphenyltin (Me5) to Wistar rats (female) at the maximum tolerated dose (MTD) of 2000 mg/kg and 750 mg/kg, respectively. It was found that the introduction of Me3 and Me5 do not cause significant structural changes in liver, and the disorders are of a functional nature. The results of this work allow us to conclude that the hepatotoxicity of organotin compounds containing 2,6-di-tert-butylphenol is low, which opens up broad prospects for studying these compounds as candidates for antitumor drugs.
Keywords:
organotin compounds
hepatotoxicity
medicinal liver damage
antitumor drugs
References:
- Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu / Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shahzadovoj. M.: MNIOI im. P.A. Gercena − fil-ial FGBU «NMIC radiologii» Minzdrava Rossii. 2020; 239 s.
- Azad A., Chang P., Deepika D., et al. Real world experience of drug induced liver injury in patients undergoing chemotherapy. J. Clin. Gastroenterol. Hepatol. 2018; 2(3):18.
- Polunina T.E., Maev I.V. Lekarstvennyj gepatit. Consilium medicum. Gastrojenterologija. 2008; 1:3–10.
- Ivashkin V.T., Baranovskij A.Ju., Rajhel'son K.L. i dr. Lekarstvennye porazhenija pecheni (klinicheskie rekomendacii dlja vrachej). Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2019; 29(1):101–131.
- Banti C.N., Hadjikakou S.K., Sismanoglu T., Hadjiliadis N. Anti-proliferative and antitumor activity of organotin (IV) compounds. An overview of the last decade and future perspectives. J. Inorg. Biochem. 2019; 194:114–152.
- Shpakovsky D.B., Banti C.N., Mukhatova E.M. et al. Synthesis, antiradical activity and in vitro cytotoxicity of novel organotin complexes based on 2,6-di-tert-butyl-4-mercaptophenol. Dalton Trans. 2014; 43:6880–6890.
- OECD Guideline for testing of chemicals. Acute Oral Toxicity -Fixed Dose Procedure No. 420. OECD Publishing, Paris, 2001.
- OECD, Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure. OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, 2008. https://doi.org/10.1787/9789264071049-en
- Koptjaeva K.E., Muzhikjan A.A., Gushhin Ja.A. i dr. Metodika vskrytija i izvlechenija organov laboratornyh zhivotnyh (krysy). Laboratornye zhivotnye dlja nauchnyh issledovanij. 2018; 2:71–92.
- Habriev R.U. Rukovodstvo po jeksperimental'nomu (doklinicheskomu) izucheniju novyh farmakologicheskih veshhestv. M.: Medicina, 2005; 832 s.
- Aithal G.P., Watkins P.B., Andrade R.J., et al. Review. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 2011; 89(6):806–815.
- Milaeva E.R., Tyurin V.Y., Gracheva Y.A. et al. Protective Effect of Meso-Tetrakis-(3,5-di-tert-butyl-4-hydroxyphenyl)porphyrin on the In Vivo Impact of Trimethyltin Chloride on the Antioxidative Defense System. Bioinorg. Chem. Appl. 2006; 2006:64927.